Results 51 to 60 of about 22,288 (223)
Acta Ophthalmologica, EarlyView.Abstract Purpose To describe the associations of treated neovascular AMD with the risk of disability, falls, fractures and mood disorders in a large sample representative of the French population. Methods Analyses were based on 77 582 individuals belonging to the ‘Echantillon Généraliste des Bénéficiaires’, a 1/97 random sample of the French population,
Cécile Delcourt +6 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To determine the relationship between the baseline junctional retinal sensitivity measured with microperimetry and the atrophy progression rate in eyes with geographic atrophy (GA) secondary to age‐related macular degeneration. Methods In this prospective cohort study, patients with GA were examined with fundus autofluorescence (FAF ...
Alexander Kai Thomsen +5 more
wiley +1 more source
Case Reports in Ophthalmology, 2022 We describe the results of very early pars plana vitrectomy, subretinal r-tPA, and gas tamponade in patients with subretinal macular hemorrhage secondary to neovascular age-related macular degeneration.
Filippo Confalonieri +3 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan +12 more
wiley +1 more source
Patient Reported Outcome Measures in Treatment of Neovascular Age-related Macular Degeneration
, 2021 Neovascular age-related macular degeneration (nAMD) is causing a progressive central vision loss. Intravitreal anti–vascular endothelial growth factor (anti-VEGF) treatment is often effective, but requires frequent injections for years.
Jelin, Elma
core +1 more source
Management of neovascular age-related macular degeneration: Taiwan expert consensus
Journal of the Formosan Medical Association, 2021 Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ...
Ling Yeung +10 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider +7 more
wiley +1 more source
Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up [PDF]
, 2016 Nadezhda P Cvetkova, Kristina Hölldobler, Philipp Prahs, Viola Radeck, Horst Helbig, David Märker Department of Ophthalmology, University of Regensburg, Regensburg, Germany Purpose: Our aim was to evaluate an optical coherence tomography (OCT)
Hölldobler K +11 more
core +1 more source
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects. [PDF]
, 2023 Anti-vascular endothelial growth factor (anti-VEGF) therapies have become the standard of care in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), resulting in a remarkable decrease in disease-related
Seelig, Eleonora +7 more
core +1 more source